ABSTRACT
Se presenta el caso de una paciente con epilepsia refractaria de lóbulo temporal debida a esclerosis mesial temporal, sometida a la primera lobectomía temporal efectuada en el Perú. El resultado ha sido exitoso, ya que la paciente continúa libre de crisis convulsivas después de más de 4 años de periodo post-operatorio. Se comentan las implicaciones de lo que puede constituir un hito en la historia de la neurología y neurocirugía en el Perú.
The case of a female patient with the diagnosis of refractory temporal lobe epilepsy due to mesial temporal sclerosis is presented. She underwent temporal lobectomy, the first intervention of this type performed in Peru. The outcome has been successful, as the patient remains seizure-free four years into her post-surgical period. The implications of what may be considered a landmark in the history of neurology and neurosurgery in Peru are commented upon.
ABSTRACT
Objetivos: describir las características clínicas y la evolución del estado epiléptico convulsivo (EEC) en pacientes adultos admitidos en el Servicio de Emergencia del Instituto Nacional de Ciencias Neurológicas de Lima, Perú entre los años 2011 y 2013. Métodos: Se realizó un estudio prospectivo de serie de casos. Resultados: Se incluyeron 28 pacientes mayores de 17 años, la mediana de edad fue 31 años. El 57% fueron hombres y el 89% tenían antecedentes de epilepsia. La principal causa del EEC fue el incumplimiento de la medicación antiepiléptica (54%). El diazepam seguido de la fenitoína fue el tratamiento antiepiléptico más empleado (75%) y la frecuencia de EEC refractario fue del 4%. Conclusiones: los pacientes fueron mayoritariamente varones, adultos jóvenes, con antecedentes de epilepsia que presentaron un EEC debido el incumplimiento de la medicación antiepiléptica y respondieron favorablemente al tratamiento con diazepam seguido de fenitoína.
Objectives: to describe the characteristics features and outcome of convulsive status epilepticus (CSE) in adult patients admitted to the Emergency Department at the Instituto Nacional de Ciencias Neurológicas in Lima, Peru between 2011 and 2013. Methods: a prospective study was conducted. Results: twenty-eight patients older than 17 years were included, the median age was 31 years old. 57% were male and 89% had a history of epilepsy. Main cause of CSE was antiepileptic medication noncompliance (54%). Diazepam followed by phenytoin was the most used therapeutic regimen (75%) and the frequency of refractory CSE was 4%. Conclusion: patients were mostly male, young adults with a history of epilepsy who presented a CSE caused by the antiepileptic medication noncompliance and the response to treatment based on diazepam followed by phenytoin was positive.
Subject(s)
Humans , Male , Young Adult , Middle Aged , Status Epilepticus , Status Epilepticus/epidemiology , Status Epilepticus/etiology , Status Epilepticus/prevention & controlABSTRACT
We report the achievements obtained, over a period of 4 years, by the collaborative partnering effort of the Epilepsy Program at Western University in Canada and the Instituto of Ciencias Neurologicas in Lima, Peru, building an epilepsy program in Peru.
Subject(s)
Epilepsy/epidemiology , Epilepsy/therapy , International Cooperation , Program Evaluation , Canada , Electroencephalography , Epilepsy/diagnosis , Female , Humans , International Educational Exchange , Longitudinal Studies , Male , Peru/epidemiology , Program Development , Treatment OutcomeABSTRACT
The 2001 classification subcommittee of the International League Against Epilepsy (ILAE) proposed to 'group JME, juvenile absence epilepsy, and epilepsy with tonic clonic seizures only under the sole heading of idiopathic generalized epilepsies (IGE) with variable phenotype'. The implication is that juvenile myoclonic epilepsy (JME) does not exist as the sole phenotype of family members and that it should no longer be classified by itself or considered a distinct disease entity. Although recognized as a common form of epilepsy and presumed to be a lifelong trait, a long-term follow-up of JME has not been performed. To address these two issues, we studied 257 prospectively ascertained JME patients and encountered four groups: (i) classic JME (72%), (ii) CAE (childhood absence epilepsy) evolving to JME (18%), (iii) JME with adolescent absence (7%), and (iv) JME with astatic seizures (3%). We examined clinical and EEG phenotypes of family members and assessed clinical course over a mean of 11 +/- 6 years and as long as 52 years. Forty per cent of JME families had JME as their sole clinical phenotype. Amongst relatives of classic JME families, JME was most common (40%) followed by grand mal (GM) only (35%). In contrast, 66% of families with CAE evolving to JME expressed the various phenotypes of IGE in family members. Absence seizures were more common in family members of CAE evolving to JME than in those of classic JME families (P < 0.001). Female preponderance, maternal transmission and poor response to treatment further characterized CAE evolving to JME. Only 7% of those with CAE evolving to JME were seizure-free compared with 58% of those with classic JME (P < 0.001), 56% with JME plus adolescent pyknoleptic absence and 62% with JME plus astatic seizures. Long-term follow-up (1-40 years for classic JME; 5-52 years for CAE evolving to JME, 5-26 years for JME with adolescent absence and 3-18 years for JME with astatic seizures) indicates that all subsyndromes are chronic and perhaps lifelong. Seven chromosome loci, three epilepsy-causing mutations and two genes with single nucleotide polymorphisms (SNPs) associating with JME reported in literature provide further evidence for JME as a distinct group of diseases.
Subject(s)
Myoclonic Epilepsy, Juvenile/genetics , Adolescent , Adult , Age of Onset , Child , Chronic Disease , Disease Progression , Electroencephalography , Family , Female , Follow-Up Studies , Humans , Male , Myoclonic Epilepsy, Juvenile/classification , Phenotype , Polymorphism, Single Nucleotide , Prognosis , Sex FactorsABSTRACT
Idiopathic generalized epilepsies (IGEs) comprise at least 40% of epilepsies in the United States, 20% in Mexico, and 8% in Central America. Here, we review seizure phenotypes across IGE syndromes, their response to treatment and advances in molecular genetics that influence nosology. Our review included the Medline database from 1945 to 2005 and our prospectively collected Genetic Epilepsy Studies (GENESS) Consortium database. Generalized seizures occur with different and similar semiologies, frequencies, and patterns, ages at onset, and outcomes in different IGEs, suggesting common neuroanatomical pathways for seizure phenotypes. However, the same seizure phenotypes respond differently to the same treatments in different IGEs, suggesting different molecular defects across syndromes. De novo mutations in SCN1A in sporadic Dravet syndrome and germline mutations in SCN1A, SCN1B, and SCN2A in generalized epilepsies with febrile seizures plus have unraveled the heterogenous myoclonic epilepsies of infancy and early childhood. Mutations in GABRA1, GABRG2, and GABRB3 are associated with absence seizures, while mutations in CLCN2 and myoclonin/EFHC1 substantiate juvenile myoclonic epilepsy as a clinical entity. Refined understanding of seizure phenotypes, their semiology, frequencies, and patterns together with the identification of molecular lesions in IGEs continue to accelerate the development of molecular epileptology.
